Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD38-LMP1 tandem CAR-T cells
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD38-LMP1 tandem CAR-T cells are second-generation chimeric antigen receptor (CAR) T cells engineered to simultaneously target CD38 and latent membrane protein 1 (LMP1). Developed by researchers at the First Affiliated Hospital of Zhengzhou University and Baylor College of Medicine, these tandem CAR-T cells are designed to treat natural killer/T-cell lymphoma (NKTCL), an aggressive hematologic malignancy strongly associated with Epstein-Barr virus (EBV) infection. By targeting both CD38 (highly expressed on NKTCL cells) and LMP1 (an EBV-encoded oncogenic protein), the tandem CAR-T cells aim to enhance cytolytic activity and prevent antigen escape, a common mechanism of resistance in single-target CAR-T therapies. Preclinical studies in vitro and in vivo have demonstrated robust anti-tumor activity, target-dependent activation, and inflammatory cytokine production.
- Other names
- CD38-LMP1 Tan CAR 1CD-38-LMP1 Tan CAR 1CD 38-LMP1 Tan CAR 1CD38-LMP1 Tan CAR 2CD-38-LMP1 Tan CAR 2CD 38-LMP1 Tan CAR 2CD38-LMP1 Tan CAR-T cellsCD-38-LMP1 Tan CAR-T cellsCD 38-LMP1 Tan CAR-T cellsCD38-LMP1 tandem CAR-TCD-38-LMP1 tandem CAR-TCD 38-LMP1 tandem CAR-TCD38/LMP1 TanCAR-T cellsCD38/LMP1 bispecific CAR-T cells
Beyond the preview
Go deeper on CD38-LMP1 tandem CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD38-LMP1 tandem CAR-T cells.